rna
interfer
rnai
technolog
becom
power
tool
function
genom
also
allow
rapid
drug
target
discoveri
vitro
valid
target
cell
cultur
furthermor
rnai
repres
promis
novel
therapeut
option
treat
human
diseas
particular
cancer
select
gene
silenc
rnai
achiev
essenti
two
nucleic
acid
base
method
cytoplasm
deliveri
short
doublestrand
ds
interf
rna
oligonucleotid
sirna
gene
silenc
effect
transient
natur
possibl
suitabl
applic
ii
nuclear
deliveri
gene
express
cassett
express
short
hairpin
rna
shrna
process
like
endogen
interf
rna
lead
stabl
gene
downregul
process
involv
use
nucleic
acid
base
drug
highli
charg
cross
cell
membran
free
diffus
therefor
vivo
deliveri
rnai
therapeut
must
use
technolog
enabl
rnai
therapeut
travers
biolog
membran
barrier
vivo
virus
vector
deriv
carri
precis
task
becom
major
deliveri
system
shrna
summar
compar
differ
current
use
viral
deliveri
system
give
exampl
vivo
applic
indic
trend
new
develop
replic
virus
shrna
deliveri
cancer
cell
human
genom
project
unravel
human
genet
code
spinoff
technic
improv
also
inspir
genom
sequenc
multitud
organ
howev
sinc
sequenc
data
alon
suffici
identifi
gene
function
gene
knockout
knockin
strategi
replenish
result
order
analyz
result
phenotyp
chang
defin
gene
function
knowledg
vivo
phenotyp
knock
gene
product
prerequisit
assess
therapeut
potenti
inhibitor
specif
target
drug
develop
knockout
anim
model
becom
import
howev
gener
transgen
anim
still
labor
cost
intens
altern
select
silenc
achiev
exploit
rna
interfer
rnai
machineri
host
cell
sinc
discoveri
fire
mello
c
elegan
gain
nobel
prize
tuschl
et
al
mammalian
cell
rnai
quickli
adopt
research
commun
versatil
tool
wide
rang
applic
revers
genet
high
throughput
screen
drug
target
key
therapeut
advantag
use
rnai
lie
abil
specif
potent
knockdown
express
diseasecaus
gene
known
sequenc
although
rnai
comparison
knockout
strategi
abl
knockdown
gene
express
simpl
vivo
inhibit
singl
gene
product
rnai
yield
phenotyp
compar
classic
knockout
anim
use
therapeut
target
identif
valid
furthermor
basic
research
benefit
vivo
rnai
strategi
chang
depend
desir
outcom
exampl
condit
gene
knockout
util
induc
promot
use
unravel
molecular
pathway
investig
function
genom
rnai
basic
pathway
eukaryot
cell
contrast
activ
cascad
cell
upon
exposur
long
doubl
strand
rna
lead
nonspecif
rna
degrad
rnai
mediat
short
rna
duplex
hitchhik
cellular
pathway
silenc
gene
sequencespecif
manner
mrna
level
perfectli
complementari
dsrna
short
hairpin
rna
shrna
chop
dicer
ribonucleas
iii
rnase
iii
famili
member
small
interf
rna
sirna
duplex
nt
length
symmetr
nucleotid
nt
overhang
use
sirna
duplex
often
accompani
offtarget
effect
avoid
reduc
ad
backbon
modif
duplex
alter
key
thermodynam
bind
properti
dicerchop
duplex
incorpor
protein
complex
call
rnainduc
silenc
complex
risc
subsequ
unwound
multifunct
protein
argonaut
contain
within
risc
activ
risc
contain
antisens
strand
guid
strand
sirna
thought
direct
sirna
target
mrna
ident
sequenc
lead
degrad
target
mrna
activ
risc
complex
move
destroy
addit
mrna
target
propag
gene
silenc
featur
rnai
mechan
induc
synthet
sirna
provid
knockdown
effect
seven
day
rapidli
divid
cell
sever
week
rest
cell
thu
rnai
provid
simpl
inexpens
select
method
gene
inhibit
high
success
rate
eukaryot
produc
variou
type
small
rna
function
divers
pathway
sinc
speci
activ
form
small
rna
often
indistinguish
biochem
function
convent
group
two
class
base
origin
biogenesi
microrna
mirna
small
interf
rna
sirna
mirna
gener
dsrna
region
hairpinshap
precursor
wherea
sirna
deriv
long
doublestrand
rna
dsrna
mirna
transcrib
primari
mirna
transcript
primirna
process
within
nucleu
complex
consist
rnase
iii
enzym
drosha
doublestrand
rnabind
protein
dgcr
premirna
export
nucleu
cytoplasm
cytoplasm
premirna
enter
pathway
mention
sirna
end
mirna
sirna
bind
mrna
induc
mrna
cleavag
translat
repress
cleavageindepend
mrna
decay
mirna
predominantli
induc
translat
repress
due
imperfect
pair
target
mrna
sirna
often
form
perfect
duplex
target
therefor
direct
cleavag
target
mrna
site
complementar
figur
schemat
summar
rnai
machineri
host
cell
rnaibas
therapi
human
cancer
one
rapidli
progress
applic
viral
deliv
shrna
theoret
use
appropri
design
sirna
rnai
machineri
exploit
silenc
almost
gene
genom
inde
alreadi
report
synthet
sirna
capabl
knock
target
variou
diseas
vivo
experiment
test
effect
target
gene
involv
cancerassoci
cellular
pathway
either
oncogen
particularli
fusion
oncogen
due
uniqu
link
certain
tumor
cell
antiapoptot
gene
addit
gene
play
role
tumorhost
interact
factor
involv
angiogenesi
innat
immun
mediat
resist
chemoor
radiotherapi
target
interfer
instanc
cancer
diseas
ovarian
cancer
bone
cancer
current
investig
success
treat
sirna
vivo
interest
therapi
field
area
mirnacaus
malign
direct
effect
mirna
believ
regul
mani
onethird
human
gene
transcript
messeng
rna
implic
mani
human
diseas
use
gene
therapi
manipul
mirna
level
repres
attract
new
approach
control
gene
express
identifi
target
effect
therapeut
import
role
mirna
cancer
pathogenesi
emerg
last
year
mani
report
reveal
numer
exampl
link
dysregul
express
mirna
cancer
recent
result
demonstr
express
singl
mirna
vivo
revers
diseas
progress
liver
cancer
model
open
whole
new
replac
therapi
field
cancer
treatment
use
rnai
human
pathogen
virus
also
excel
target
rnai
exogen
sequenc
uniqu
host
minim
offtarget
side
effect
due
treatment
strategi
target
essenti
viral
gene
prevent
viral
prolifer
howev
one
keep
mind
virus
acquir
abil
counteract
antivir
rnai
exampl
success
rnai
approach
combat
human
pathogen
virus
includ
target
hepat
b
viru
hbv
human
papilloma
viru
sever
acut
respiratori
syndrom
sar
coronaviru
respiratori
syncyti
viru
rsv
infect
therapeut
relev
field
metabol
diseas
cardiac
disord
human
neurodegen
diseas
inherit
genet
diseas
recent
publish
studi
show
success
sirna
target
member
mammalian
serin
protein
convertas
famili
typic
function
proteolyt
process
matur
secretori
protein
first
famili
member
implic
dominantli
inherit
form
hypercholesterolemia
target
sirna
lower
plasma
cholesterol
henc
offer
auspici
therapeut
approach
control
diseas
clinic
trial
coronari
arteri
diseas
also
underway
use
rna
therapeut
agent
aim
silenc
one
gene
cmyc
respons
caus
arteri
reclos
stent
insert
restenosi
anoth
studi
show
almost
complet
resolv
liver
fibrosi
prolong
surviv
vivo
rat
follow
treatment
synthet
modifi
sirna
efficaci
highlight
new
therapeut
potenti
revers
human
liver
cirrhosi
tabl
provid
rough
overview
current
clinic
trial
sirna
therapeut
first
clinic
trial
conduct
use
sirna
aim
age
relat
macular
degener
amd
earli
compani
sirna
present
first
figur
schemat
overview
mechan
rna
silenc
host
cell
lead
transcript
silenc
retrovir
deliveri
shmirna
retrovirus
vector
deliv
therapeut
shrnaexpress
transgen
integr
genom
host
cell
lead
stabl
shrna
express
express
shrna
requir
activ
endogen
exportin
nuclear
export
sever
protein
recruit
form
dimer
dicer
receiv
subsequ
cleav
dsrna
gener
duplex
sirna
nt
overhang
sirna
activ
rnainduc
silenc
complex
risc
unwind
rna
recruit
guid
strand
target
mrna
subsequ
cleav
degrad
figur
schemat
dicer
risc
complex
vari
depend
cellular
process
ever
clinic
data
rnaibas
drug
compound
formerli
amd
compani
opoko
health
launch
first
ever
sirna
phase
iii
trial
use
bevasiranib
firstinclass
sirna
drug
design
silenc
gene
produc
vascular
endotheli
growth
factor
vegf
believ
larg
respons
vision
loss
wet
amd
unfortun
march
phase
iii
trial
termin
ahead
schedul
due
review
independ
data
committe
found
although
drug
show
activ
trial
unlik
meet
primari
endpoint
opoko
health
miami
florida
press
releas
one
keep
mind
clinic
trial
perform
unmodifi
sirna
doubt
show
good
result
appar
convinc
enough
human
therapi
failur
first
clinic
phase
iii
studi
highlight
need
second
gener
sirna
therapeut
exampl
shrnaexpress
cassett
well
effici
transfer
vehicl
cassett
princip
mani
differ
way
trigger
rnai
propos
clinic
applic
rnai
incorpor
chemic
synthes
nt
sirna
duplex
nt
overhang
mode
administr
transient
sinc
intracellular
concentr
sirna
dilut
cell
divis
furthermor
duplex
sirna
neg
charg
polym
therefor
easili
penetr
hydrophob
cellular
membran
without
assist
carrier
addit
unprotect
unmodifi
sirna
gener
rapidli
degrad
serum
rnase
contrast
intracellularli
express
short
hairpin
rna
mediat
longterm
knockdown
target
transcript
long
shrna
transcrib
therapi
chronic
diseas
exampl
requir
exactli
longterm
target
gene
downregul
ideal
deliveri
vehicl
therefor
facilit
endosom
lysosom
escap
case
shrna
payload
must
penetr
nuclear
membran
virus
vector
deriv
carri
precis
task
therefor
becom
major
deliveri
system
shrna
rnai
cell
induc
intracellularli
express
short
hairpin
rna
either
shrna
synthet
mirna
basic
transcript
unit
shrna
sens
antisens
sequenc
connect
loop
unpair
nucleotid
mirna
stem
loop
typic
express
part
larger
primari
transcript
primirna
artifici
mirna
natur
resembl
endogen
rnai
substrat
amen
polii
transcript
may
seem
attract
therapi
date
shrnaand
artifici
mirnabas
strategi
compar
conflict
result
seem
choic
alway
depend
strategi
desir
outcom
figur
experiment
combin
rnai
viral
gene
therapi
vector
power
approach
certain
scenario
spatiotempor
control
gene
silenc
highli
critic
persist
suppress
target
mandatori
success
design
viral
rnai
vector
becam
possibl
upon
discov
promoterdriven
express
short
hairpin
rna
shrna
induc
rnai
machineri
strategi
involv
clone
oligonucleotid
contain
sirna
sequenc
plasmid
viral
vector
endogen
express
shrna
subsequ
process
cytoplasm
sirna
fortun
shrna
express
cassett
extrem
limit
size
mean
packag
even
smallest
known
viral
vector
next
section
review
exist
viral
vector
system
adenovirus
adv
belong
famili
adenovirida
adenovir
vector
frequent
use
experiment
gene
therapi
clinic
gene
therapi
trial
current
underway
use
adenoviru
adenovirus
mediums
nonenvelop
virus
nucleocapsid
linear
dsdna
genom
initi
bind
follow
secondari
interact
penton
base
protein
interact
integrin
result
entri
virion
host
cell
adenovir
vector
exhibit
clear
tissu
tropism
howev
relev
surfac
receptor
often
absent
tissu
interest
especi
tumor
cell
connect
rnai
therapi
larg
packag
capac
gutless
adenoviru
vector
could
problem
small
shrna
cassett
sinc
might
jeopard
genet
vector
stabil
disadvantag
adv
vector
problem
repeat
administr
trigger
strong
immun
respons
potenti
limit
effect
certain
therapeut
set
addit
frequent
describ
liver
toxic
make
adenovir
vector
unsuit
least
handl
care
human
therapi
today
adenovir
vector
common
deliveri
method
introduc
shrnaexpress
cassett
target
cell
vitro
commerci
avail
sever
public
report
use
adenovir
vector
transduc
rnaibas
therapi
vivo
first
studi
employ
adenovir
vector
vivo
rnai
publish
applic
central
nervou
system
data
valid
outstand
promis
oncolyt
adenovir
vector
tumorrestrict
shrna
express
although
still
limit
mention
differ
review
summar
adenovir
shrna
deliveri
great
detail
eg
interest
reader
refer
adenoassoci
viral
aav
vector
also
test
clinic
studi
multipl
tissu
aav
one
smallest
virus
belong
genu
dependoviru
famili
parvovirida
small
singlestrand
dna
genom
kb
apathogen
human
least
accord
current
knowledg
genom
contain
two
gene
replac
foreign
one
leav
termin
itr
allow
highlevel
express
insert
howev
kb
packag
limit
aav
still
suffici
accommod
least
eight
individu
shrna
express
cassett
viru
replicationdefect
recent
requir
adenoviru
replic
product
vector
new
method
produc
recombin
aav
use
singl
adenovir
gene
made
adenovir
coinfect
aavproduc
cell
dispens
although
wildtyp
aav
preferenti
integr
within
specif
region
human
chromosom
recombin
aav
engin
ineffici
integr
sinc
lack
aav
rep
protein
contrast
adenoviru
pseudotyp
aav
permit
entri
retarget
allow
deliveri
shrna
cassett
specif
cell
tissu
furthermor
aavvector
show
low
reactiv
cellular
immun
respons
date
sever
report
alreadi
describ
develop
aav
vector
deliv
express
antitumor
shrna
vitro
well
small
anim
model
one
studi
exploit
aav
express
shrna
highli
express
cancer
repeat
intratumor
administr
caus
antiprolif
proapoptot
effect
tumor
cell
anoth
recent
studi
dealt
shrna
mediat
downregul
androgen
receptor
ar
system
deliveri
recombin
aav
vector
stabli
express
shrna
ar
gene
elimin
prostat
xenograft
nude
mice
detail
possibl
applic
aav
shrna
deliveri
found
elsewher
eg
adenovir
adv
adenoassoci
viru
aav
vector
nonintegr
therefor
pose
minim
risk
insert
mutagenesi
time
may
repres
neg
aspect
sinc
genet
inform
less
stabli
conserv
may
lost
repetit
cell
divis
although
vector
transduc
divid
nondivid
cell
allow
effici
gene
transfer
inadequ
longterm
gene
replac
therapi
use
gene
deliveri
vector
base
retrovirus
introduc
earli
mann
et
al
singlestrand
ss
rna
virus
belong
famili
retrovirida
replic
doublestrand
dna
intermedi
integr
genom
stabli
host
cell
dna
allow
longterm
express
insert
therapeut
gene
subfamili
orthoretrovirina
compris
differ
genii
exampl
simplest
gammaretrovirus
eg
mlv
complex
lentivirus
eg
hiv
viral
genom
approxim
kb
contain
least
three
gene
gag
code
core
protein
pol
code
revers
transcriptas
env
code
viral
envelop
protein
complex
retrovirus
encod
number
accessori
protein
involv
regul
viral
replic
host
cell
respons
viru
end
genom
long
termin
repeat
ltr
contain
promoterenhanc
region
sequenc
involv
integr
addit
sequenc
requir
packag
viral
rna
psi
retrovir
entri
genom
integr
requir
viral
protein
synthesi
therefor
viral
gene
vector
genom
replac
foreign
sequenc
vector
particl
produc
packag
cell
line
provid
viral
protein
tran
cell
releas
vector
genom
packag
infecti
particl
free
contamin
helper
viru
replicationcompet
recombin
viru
henc
viral
protein
produc
transduct
avoid
induc
advers
effect
immun
respons
vector
particl
prevent
subsequ
spread
vector
exit
cell
retrovirus
vector
acquir
cellderiv
lipid
bilay
contain
insert
glycoprotein
env
bud
host
cell
membran
env
protein
mediat
attach
fusion
next
host
cell
membran
viral
membran
result
releas
viral
capsid
particl
contain
genet
materi
cytoplasm
play
central
role
target
retrovir
entri
target
cell
sinc
env
interact
specif
cellular
protein
accordingli
determin
viral
tropism
alter
env
gene
product
one
possibl
way
manipul
target
cell
rang
increas
vector
safeti
success
approach
enhanc
safeti
tumor
therapi
engin
proteaseactiv
env
protein
system
virus
remain
noninfecti
env
becom
activ
via
cleavag
secret
membranebound
proteas
recogn
engin
proteas
substrat
detail
inform
found
elsewher
select
infect
tumor
cell
combin
transfer
antitumor
shmisirna
attract
strategi
cancer
therapi
focu
current
research
sever
strategi
explor
summari
found
elsewher
use
retrovir
vector
effici
introduc
shrna
express
cassett
target
cell
exploit
mani
year
retrovirus
among
first
vector
use
transfer
vehicl
hairpinrna
express
plasmid
brummelcamp
et
al
use
retrovirus
highlight
extrem
specif
rnai
concept
fan
interest
use
rnai
therapeut
applic
cancer
therapi
number
public
follow
use
retrovir
vector
base
murin
leukemia
viru
mlv
transfer
vehicl
shrnaexpress
cassett
promin
work
paddison
et
al
bern
et
al
publish
group
gener
retrovirusbas
shrna
express
librari
capabl
target
around
third
human
gene
librari
show
promis
gene
analysi
discoveri
sinc
enabl
largescal
genet
screen
offer
tool
identifi
gene
involv
specif
biolog
process
work
follow
appli
retrovir
deliv
shrna
high
throughput
screen
detail
view
pioneer
experi
found
elsewher
eg
retrovirus
still
current
use
transfer
vehicl
shrna
one
recent
studi
report
prolong
suppress
product
infect
tcell
line
retrovir
mlv
deliv
shrna
target
sequenc
locat
within
nfb
bind
motif
promot
express
shrna
express
tcell
line
suppress
year
lentivirus
lv
constitut
subclass
retrovirus
also
carri
two
copi
singlestrand
rna
genom
envelop
capsid
among
differ
speci
genu
lentivirina
promin
human
immunodefici
viru
hiv
well
other
felin
immunodefici
viru
fiv
simian
immunodefici
viru
siv
contrast
retrovir
vector
mention
lentivir
vector
capabl
transduc
divid
nondivid
cell
eg
neuron
make
prefer
candid
vector
nervou
system
applic
lentivir
vector
accommod
larg
kb
amount
dna
less
immunogen
adenovir
vector
mostli
use
local
applic
well
ex
vivo
gene
therapi
complex
simpl
retrovirus
contain
addit
six
protein
tat
rev
vpr
vpu
nef
vif
sinc
nativ
virus
caus
fatal
diseas
human
nonrepl
virus
use
transgen
express
current
packag
cell
usual
transfect
separ
plasmid
encod
env
gene
transgen
construct
packag
construct
suppli
structur
regulatori
gene
tran
advanc
safest
form
engin
selfinactiv
sin
vector
region
utr
delet
heterolog
promot
cmv
ensur
transcript
entir
vector
mrna
strategi
exclud
risk
recreat
replic
compet
wildtypelik
virus
chanc
like
gammaretrovirus
lentivir
vector
amen
pseudotyp
exampl
pseudotyp
env
vsvg
broaden
tropism
support
uptak
otherwis
refractori
cell
human
hematopoiet
embryon
stem
cell
lentivirus
commonli
use
vector
transfer
shrnaexpress
cassett
today
deliveri
shrna
target
cell
via
lentivir
vector
effici
variou
compani
offer
method
vitro
experi
past
year
sever
adapt
novel
techniqu
emerg
improv
condit
transgen
express
assidu
scientist
choos
differ
wellestablish
system
experiment
setup
exampl
use
lentivir
vector
vector
system
shrna
innumer
touch
mani
case
lentivir
vector
employ
success
regul
target
gene
brain
local
inject
upcom
clinic
trial
one
applic
rnai
involv
ex
vivo
lentivir
vector
deliveri
shrna
express
cassett
hematopoiet
stem
cell
collect
patient
infect
hiv
transduc
cell
must
reinfus
patient
therapeut
benefit
vivo
lv
also
use
creat
transgen
anim
one
drawback
fact
vector
becom
silenc
longterm
cultur
differ
review
give
exhaust
survey
great
detail
eg
insect
baculoviru
earli
test
stage
possibl
vector
vivo
use
vector
shrna
report
baculovirusdeliv
shrna
compris
manag
amount
public
vector
base
baculoviru
transport
larg
amount
genet
data
leav
copiou
space
creativ
combin
gene
therapi
silenc
vector
furthermor
baculoviru
unabl
replic
express
viral
protein
mammalian
cell
make
viru
safe
gene
therapi
candid
first
development
stage
baculovirusbas
shrna
express
current
use
target
differ
viral
infect
exampl
hcv
replic
well
influenza
viru
b
howev
effect
transient
sinc
major
limit
baculovir
transduct
vector
short
durat
transgen
express
way
overcom
exampl
insert
epsteinbarr
viru
sequenc
baculoviru
vector
improv
longterm
express
still
long
way
go
promis
result
find
way
human
therapi
trial
effect
genebas
therapi
requir
effici
deliveri
therapeut
gene
target
mammalian
cell
also
continu
gene
express
realiz
convent
gene
therapi
approach
yet
deliv
signific
therapeut
benefit
cancer
treatment
combin
advanc
past
year
reignit
interest
use
replic
virus
big
advantag
replic
virus
contrast
replicationdefect
vector
abl
spread
tumor
tissu
viral
propag
set
transducedinfect
tumor
cell
becom
virusproduc
cell
therebi
sustain
infect
beyond
initi
inoculum
idea
led
novel
cancer
therapi
oncolyt
virotherapi
recent
advanc
molecular
biolog
allow
design
sever
genet
modifi
virus
adenoviru
herp
simplex
viru
specif
replic
kill
tumor
cell
also
reoviru
polioviru
paramyxoviru
vaccinia
viru
vesticular
stomat
viru
exploit
virus
possess
intrins
oncolyt
activ
sinc
infect
final
lead
host
cell
death
contrast
lv
mlv
oncolyt
activ
shrnaexpress
cassett
use
fulfil
effector
function
fulli
replic
lentivirus
hiv
due
calamit
risk
benefit
ratio
healthi
patient
discuss
gene
transfer
vehicl
howev
alreadi
infect
patient
gene
transfer
use
condit
replic
lentivir
vector
consider
strategi
base
exploit
hivbas
lentivir
vector
carri
antisens
sequenc
target
hiv
treat
hiv
infect
enter
clinic
trial
trial
evalu
condit
replic
vector
pseudotyp
vsvg
express
antisens
gene
hiv
envelop
novel
idea
retain
full
hiv
ltr
vector
result
upregul
express
antisens
upon
wildtyp
hiv
infect
cell
studi
show
improv
cellular
respons
hiv
four
five
subject
three
experienc
improv
cell
memori
respons
oppos
antisensestrategi
use
anoth
group
studi
shrnaexpress
cassett
transgen
replic
use
doxycyclindepend
variant
viru
replic
condit
presenc
doxycyclin
dox
effici
deliv
antinef
shrna
cell
suscept
infect
dox
withdraw
gener
cell
contain
silent
integr
proviru
activ
shrna
express
cassett
remov
nefsequ
vector
genom
avoid
vector
selftarget
inhibit
replic
transduc
cell
vitro
use
condit
replic
lentivir
vector
seem
promis
treatment
infect
use
shrna
may
prove
benefici
therapi
spectrum
uniqu
among
replic
virus
develop
oncolyt
agent
retrovirus
particular
mlvbase
virus
replic
without
immedi
lysi
host
cell
maintain
viral
persist
stabl
integr
retrovirus
studi
extens
almost
year
work
culmin
first
clinic
trial
use
replic
mlv
vivo
mlv
exhibit
tumor
select
due
inabl
infect
quiescent
cell
achiev
highli
select
stabl
gene
transfer
throughout
entir
solid
tumor
vivo
effici
even
initi
inocul
moi
low
one
obstacl
overcom
tumor
therapi
use
replic
compet
retrovirus
restrict
size
insert
transgen
size
mlv
genom
limit
roughli
kb
viral
gene
replac
transgen
one
possibl
overcom
restrict
engin
mlv
semirepl
set
idea
split
viral
genom
onto
two
transcompl
vector
carri
genet
inform
either
gagpol
env
andor
transgen
togeth
alon
vector
contain
genet
materi
necessari
replic
vector
product
upon
cell
transfect
other
develop
idea
gagpol
env
gene
split
two
viral
genom
duo
allow
copropag
two
differ
transgen
offer
backup
therapeut
opportun
effect
first
gene
product
wane
due
develop
drug
resist
mean
vector
replic
shut
transgen
suicid
gene
split
genom
also
enhanc
capac
insert
therapeut
gene
construct
split
viral
genom
use
fluoresc
protein
visual
monitor
viral
replic
result
srrv
replic
compet
virus
contain
complet
genom
also
use
carri
transgen
logg
kasahara
conduct
studi
test
insert
capac
replic
virus
found
mlv
contain
insert
kb
replic
slightli
attenu
kinet
compar
wildtyp
effici
spread
transgen
vivo
administr
mani
report
describ
replic
mlv
gene
therapi
use
insert
suicid
gene
pioneer
replic
mlv
transfer
vehicl
shrna
amplifi
shrna
deliveri
replic
mlv
construct
express
shrna
control
rna
pol
iii
promot
insert
cassett
interfer
significantli
viral
fit
vector
genet
stabl
function
silenc
target
gene
express
result
show
replic
mlv
excel
tool
effici
deliveri
express
shrna
great
potenti
function
genom
might
suitabl
vivo
cancer
gene
therapi
combin
effici
entri
target
current
focus
vivo
studi
use
virus
look
forward
promis
result
rnai
technolog
becom
power
tool
key
method
gene
therapi
scientist
hand
although
effect
rnai
undoubt
still
limit
exploit
technolog
properli
due
ineffici
deliveri
distribut
shrnacassett
target
cell
focus
viral
deliveri
shrna
highlight
virus
vector
deriv
excel
candid
deliv
shrna
desir
tissu
cell
discuss
differ
method
viral
deliveri
shrna
express
cassett
use
convent
method
reveal
promis
new
strategi
util
replic
retrovirus
